An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) - Kinarus COVID-19 Study

Start Date09 Mar 2021

Sponsor / Collaborator

Kinarus AG

EUCTR2005-003495-38-GR / Not yet recruitingPhase 2

Part A: A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX) therapy.Part B: A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 1 dose of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX) therapy

Start Date27 Feb 2006

Sponsor / Collaborator-

EUCTR2005-003694-25-IT / Not yet recruitingNot Applicable

A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoid arthritis RA . - ND

Start Date12 Jan 2006

Sponsor / Collaborator

Roche Holding AG

100 Clinical Results associated with Pamapimod

100 Translational Medicine associated with Pamapimod

100 Patents (Medical) associated with Pamapimod

Literatures (Medical) associated with Pamapimod

01 Oct 2023·iScience

The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients

Article

Author: Vehreschild, Maria J G T ; Bausch, Alexander ; Soldatovic, Ivan ; Fumeaux, Thierry ; Wright, Matthew ; Berger, Claudia ; Vilimanovich, Urosh

The combination of pamapimod and pioglitazone (KIN001) has a synergetic antiviral, anti-inflammatory, and antifibrotic activity, which may prevent evolution toward COVID-19-associated severe respiratory failure. In a randomized, placebo-controlled, double-blind, phase 2, multicenter trial, 128 non-critically ill hospitalized patients with confirmed COVID-19 were treated with KIN001 or a placebo for 28 days. The proportion of patients alive and free of oxygen or respiratory support at the end of the therapy was lower than anticipated but not different in the two groups (KIN001 n = 19, 29%, placebo n = 21, 33%). 85 participants had at least one adverse event, with no difference in the number and distribution of events between the two groups. The clinical trial was stopped for futility, mainly due to a lower-than-expected incidence of the primary endpoint. KIN001 was safe and well-tolerated but had no significant effect on clinical outcome.

01 Oct 2021·Computers in Biology and MedicineQ3 · ENGINEERING & TECHNOLOGY

Repurposing of gastric cancer drugs against COVID-19

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Mittal, Nitish ; Singh, Vishal ; Rathore, Anuranjan Singh ; Jha, Hem Chandra ; Doharey, Pawan Kumar ; Sahoo, Amaresh Kumar ; Sharma, Bechan ; Sonkar, Charu ; Kashyap, Dharmendra

Corona Virus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global pandemic. Additionally, the SARS-CoV-2 infection in the patients of Gastric Cancer (GC; the third leading cause of death in the world) pose a great challenge for the health management of the patients. Since there have been uncertainties to develop a new drug against COVID-19, there is an urgent need for repurposing drugs that can target key proteins of both SARS-CoV-2 and GC. The SARS-CoV-2-RdRp protein contains the NiRAN domain, which is known to have kinase-like folds. A docking study of the FDA approved drugs against GC was performed using AutoDock 4.2 and Glide Schrodinger suite 2019 against SARS-CoV-2-RdRp protein. MMGBSA and MD simulation studies were performed to investigate the binding and stability of the inhibitors with the target protein. In this study, we have found 12 kinase inhibitors with high binding energies namely Baricitinib, Brepocitinib, Decernotinib, Fasudil, Filgotinib, GSK2606414, Peficitinib, Ruxolitinib, Tofacitinib, Upadacitinib, Pamapimod and Ibrutinib. These FDA approved drugs against GC can play a key role in the treatment of COVID-19 patients along with GC as comorbidity. We also hypothesize that JAK, ITK, Rho-associated kinases, FGFR2, FYN, PERK, TYK2, p38-MAPK and SYK kinases can be considered as key therapeutic targets in COVID-19 treatment. Taken altogether, we have proposed the SARS-CoV-2-RdRp as a potential therapeutic target through in-silico studies. However, further in-vitro and in-vivo studies are required for the validation of the proposed targets and drugs for the treatment of COVID-19 patients already suffering from GC.

01 Dec 2020·Journal of Bone and Mineral Research

The Novel p38 Inhibitor, Pamapimod, Inhibits Osteoclastogenesis and Counteracts Estrogen-Dependent Bone Loss in Mice

Author: Zhao, Xiangde ; Wan, Xinyu ; Song, Lu ; Tang, Pan ; Shen, Shuying ; Fan, Shunwu ; Huang, Bao ; Xie, Ziang ; Jie, Zhiwei ; Qin, An ; Sun, Xuewu ; Ning, Lei ; Wan, Shuanglin ; Ma, Yan ; Li, Xiang

News (Medical) associated with Pamapimod

12 Jul 2023

·www.biospace.com

Kinarus Therapeutics Announces Personnel Change

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities. Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets. His mandate as interim-CFO was, from its conception, intended to be temporary, as he is moving to California to pursue opportunities there. His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction. His mandate and our transition to a publicly listed company were completed with our recent external financial audit. We thank Subhasis for his efforts and wish him success in his future endeavors.” The CFO role at Kinarus will not be immediately filled. The Company’s financial controller provides continuity; supported by a new external advisor with significant public market experience, the Company has sufficient competencies and capacity to manage its current finances with the diligence required to properly run a listed company in Switzerland. Kinarus recently signed subordinated bridge loan agreements with existing shareholders to ensure sufficient liquidity during the period of time until the transfer of funds pursuant to a CHF1.5 million convertible loan investment in Kinarus by ChaoDian (Hangzhou) Investment Management Co (CDIM). CDIM’s investment aligns the parties’ interests and demonstrates CDIM’s confidence in achieving its mandate to find a development and commercialization partner for KN001 for treatment of IPF in China. KIN001, Kinarus’ lead product, is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway. Kinarus discovered that combining pamapimod with pioglitazone, a safe and well-tolerated marketed drug for the treatment of type 2 diabetes, leads to synergistic efficacy and increased duration of action in preclinical models of wAMD, IPF and other autoimmune/inflammation indications. KIN001 has broad patent protection in the US, EU, China, and other countries through at least 2037. Kinarus Therapeutics Holding AG ( ) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its knowledge and drug development competencies to in-license and develop mid-stage clinical assets in which they have identified an increased probability of clinical and regulatory success and a rapid path to market. Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone. Contacts Kinarus Therapeutics Holding AG Hochbergerstrasse 60C 4057 Basel, Switzerland +41 61 633 29 71 info@kinarus.com Investors & Media Chris Maggos Cohesion Bureau +41 79 367 6254 chris.maggos@cohesionbureau.com Legal disclaimer THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL NOR AN INTIMATION TO SUBMIT A PROPOSAL FOR THE ACQUISITION OF SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN ANY JURISDICTION WHERE IT IS UNLAWFUL TO BE DISTRIBUTED. Attachment Kinarus Management Change

Executive Change

29 Jun 2023

·www.globenewswire.com

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. In total, 298’358’348 shares equalling 26.09% of the Company’s share capital were represented. Approval of the 2022 Annual Report and 2022 Management Report, results appropriation, and discharge The shareholders endorsed the Annual Report, the consolidated financial statements and the statutory financial statements for 2022, the Management Report and the appropriation of the net loss. Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022. Members of the Board of Directors and the Compensation Committee re-elected Shareholders re-elected Hari Kumar, Eugene Tierney, Silvio Inderbitzin and Alexander Bausch as members of the Board of Directors, each for a term of one year. As members of the Compensation Committee, the shareholders re-elected Hari Kumar, Eugene Tierney and Silvio Inderbitzin. Statutory Auditors and Independent Proxy re-elected Shareholders re-elected Ernst & Young AG, in Basel, Switzerland as the Company’s statutory auditors for the financial year 2023 and KBT Treuhand AG Zürich, in Zurich, Switzerland as the Company’s independent proxy until the completion of the 2024 AGM. Compensation Report and remuneration for Board and Executive Management approved In a consultative vote, the shareholders endorsed the Compensation Report 2022. In separate binding votes, the shareholders agreed to the compensation for members of the Board of Directors (maximum total amount of compensation covering the period from the 2023 AGM to the 2024 AGM) and for the members of the Executive Management (maximum total amount of fixed compensation for 2023). Consent to conditional capital increase The shareholders approved a conditional capital increase by CHF 721,271.77. AGM documents The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/. From the end of next week, the minutes of the 2023 AGM will also be available. Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its knowledge and drug development competencies to in-license and develop mid-stage clinical assets in which they have identified an increased probability of clinical and regulatory success and a rapid path to market. Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone. Contacts Kinarus Therapeutics Holding AGHochbergerstrasse 60C 4057 Basel, Switzerland+41 61 633 29 71info@kinarus.comInvestors & MediaChris MaggosCohesion Bureau+41 79 367 6254chris.maggos@cohesionbureau.com Legal disclaimer THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL NOR AN INTIMATION TO SUBMIT A PROPOSAL FOR THE ACQUISITION OF SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN ANY JURISDICTION WHERE IT IS UNLAWFUL TO BE DISTRIBUTED. Attachment PDF Version

Executive ChangeLicense out/in

02 Jun 2023

·www.globenewswire.com

Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting

Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. For information on the agenda items and proposals of the board of directors as well as on how to attend the 2023 Annual General Meeting, exercise voting rights or issue voting instructions to the independent proxy, shareholders can access the invitation to the 2023 Annual General Meeting at https://ir.kinarus.com/2023-agm/. The annual report for the financial year 2022, including the management report, the statutory financial statements, the consolidated financial statements, the auditors' report and the compensation report can be downloaded from the Company’s website: https://ir.kinarus.com/financial-reporting/. The 2023 Annual General Meeting will be conducted in English. A record of the resolutions taken by the 2023 Annual General Meeting will be available after the 2023 Annual General Meeting on the Company’s website at https://ir.kinarus.com/2023-agm/. Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its knowledge and drug development competencies to in-license and develop mid-stage clinical assets in which they have identified an increased probability of clinical and regulatory success and a rapid path to market. Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone. Contacts Kinarus Therapeutics Holding AGHochbergerstrasse 60C 4057 Basel, Switzerland+41 61 633 29 71info@kinarus.comInvestors & MediaChris MaggosCohesion Bureau+41 79 367 6254chris.maggos@cohesionbureau.com Legal disclaimer THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL NOR AN INTIMATION TO SUBMIT A PROPOSAL FOR THE ACQUISITION OF SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN ANY JURISDICTION WHERE IT IS UNLAWFUL TO BE DISTRIBUTED.

License out/in

100 Deals associated with Pamapimod

External Link

KEGG	Wiki	ATC	Drug Bank
D08963	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rheumatoid Arthritis	Phase 2	DE	Roche Holding AG	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis